Emerald Bioscience (EMBI) Stock Price, News & Analysis

Company Overview

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 6.96 million shs
• Average Volume: 14.24 million shs
• Market Capitalization: $24.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EMBI Stock Analysis - Frequently Asked Questions

How do I buy shares of Emerald Bioscience?

Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Emerald Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emerald Bioscience investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Gold Resource (GORO), Meta Platforms (META), Heatwurx (PCSA), Akero Therapeutics (AKRO) and CymaBay Therapeutics (CBAY).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EMBI
• CIK: N/A
• Web: www.emeraldbio.life
• Phone: 949-336-3443
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.05 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -347.62%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 3.59
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 268,074,000
• Free Float: N/A
• Market Cap: $24.13 million
• Optionable: Not Optionable
• Beta: 0.43